Patent application number | Description | Published |
20120177596 | METHODS OF ADMINISTERING ANTI-TNFalpha ANTIBODIES - Methods of treating disorders in which TFNα activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNFα (e.g., K | 07-12-2012 |
20130004507 | METHODS OF ADMINISTERING ANTI-TNFalpha ANTIBODIES - Methods of treating disorders in which TFNα activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNFα (e.g., K | 01-03-2013 |
20130243763 | TREATMENT OF HIDRADENITIS SUPPURATIVA (HS) USING TNFalpha ANTIBODIES - Methods of treating TNFα-related disorders comprising administering TNFα inhibitors, including TNFα antibodies are described. | 09-19-2013 |
20140186368 | METHODS OF ADMINISTERING ANTI-TNFalpha ANTIBODIES - Methods of treating disorders in which TNFα activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNFα (e.g., K | 07-03-2014 |
20140271637 | METHODS OF ADMINISTERING ANTI-TNFALPHA ANTIBODIES - Methods of treating disorders in which TNFα activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNFα (e.g., K | 09-18-2014 |
20140286939 | TREATMENT OF TNFALPHA RELATED DISORDERS - Methods of treating TNFα-related disorders comprising administering TNFα inhibitors, including TNFα antibodies are described. | 09-25-2014 |
20140286940 | TREATMENT OF TNFALPHA RELATED DISORDERS - Methods of treating TNFα-related disorders comprising administering TNFα inhibitors, including TNFα antibodies are described. | 09-25-2014 |
20140286941 | TREATMENT OF TNFALPHA RELATED DISORDERS - Methods of treating TNFα-related disorders comprising administering TNFα inhibitors, including TNFα antibodies are described. | 09-25-2014 |
20140322232 | METHODS OF ADMINISTERING ANTI-TNFALPHA ANTIBODIES - Methods of treating disorders in which TNFα activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNFα (e.g., K | 10-30-2014 |
20150017175 | METHODS OF ADMINISTERING ANTI-TNFALPHA ANTIBODIES - Methods of treating disorders in which TNFα activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNFα (e.g., K | 01-15-2015 |
20150023982 | METHODS OF ADMINISTERING ANTI-TNFALPHA ANTIBODIES - Methods of treating disorders in which TNFα activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNFα (e.g., K | 01-22-2015 |
20150050216 | Uses and Compositions for Treatment of Psoriasis - The invention provides methods, uses and compositions for the treatment of psoriasis. The invention describes methods and uses for treating psoriasis, wherein a TNFα inhibitor, such as a human TNFα antibody, or antigen-binding portion thereof, is used to treat psoriasis in a subject. Also described are methods for determining the efficacy of a TNFα inhibitor for treatment psoriasis in a subject. | 02-19-2015 |
20150071939 | METHODS OF ADMINISTERING ANTI-TNFALPHA ANTIBODIES - Methods of treating disorders in which TNFα activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNFα (e.g., K | 03-12-2015 |
20150071945 | METHODS OF ADMINISTERING ANTI-TNFALPHA ANTIBODIES - Methods of treating disorders in which TNFα activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNFα (e.g., K | 03-12-2015 |
20150079101 | METHODS OF ADMINISTERING ANTI-TNFALPHA ANTIBODIES - Methods of treating disorders in which TNFα activity is detrimental via biweekly, subcutaneous administration of human antibodies, preferably recombinant human antibodies, that specifically bind to human tumor necrosis factor α (hTNFα) are disclosed. The antibody may be administered with or without methotrexate. These antibodies have high affinity for hTNFα (e.g., K | 03-19-2015 |